(0.24%) 5 103.75 points
(0.62%) 38 620 points
(0.48%) 17 735 points
(0.19%) $79.10
(-0.79%) $2.02
(0.00%) $2 309.70
(0.02%) $26.84
(0.38%) $966.30
(-0.05%) $0.932
(-0.02%) $10.99
(-0.10%) $0.797
(0.92%) $91.96
Live Chart Being Loaded With Signals
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format...
Stats | |
---|---|
本日の出来高 | 800 269 |
平均出来高 | 2.24M |
時価総額 | 598.74M |
EPS | SEK0 ( 2024-04-24 ) |
次の収益日 | ( SEK0 ) 2024-07-11 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -1.650 |
ATR14 | SEK0.00400 (0.44%) |
ボリューム 相関
Alligator Bioscience AB 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Alligator Bioscience AB 相関 - 通貨/商品
Alligator Bioscience AB 財務諸表
Annual | 2023 |
収益: | SEK58.11M |
総利益: | SEK58.11M (100.00 %) |
EPS: | SEK-0.550 |
FY | 2023 |
収益: | SEK58.11M |
総利益: | SEK58.11M (100.00 %) |
EPS: | SEK-0.550 |
FY | 2022 |
収益: | SEK35.70M |
総利益: | SEK-112.03M (-313.84 %) |
EPS: | SEK-0.530 |
FY | 2021 |
収益: | SEK12.94M |
総利益: | SEK0.00 (0.00 %) |
EPS: | SEK-0.640 |
Financial Reports:
No articles found.
Alligator Bioscience AB
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of cancer. The company also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a research collaboration with MacroGenics, Inc. to develop a novel immunotherapy. The company also has a joint research agreement with BioArctic AB (publ) to employ proprietary antibody generation technologies for developing new product candidates; and a research collaboration and license agreement with the Orion Corporation to discover and develop new bispecific antibody cancer therapeutics. Alligator Bioscience AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。